Close Menu

NEW YORK — The US Food and Drug Administration on Wednesday released a SARS-CoV-2 reference panel to assist in the development and evaluation of diagnostic tests for the virus.

The FDA said the panel is an independent performance validation step for SARS-CoV-2 tests that are being used for clinical, not research, purposes. It is available to commercial and laboratory developers interacting with the FDA through the agency's pre-Emergency Use Authorization process.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.